Sangamo Therapeutics News

Express News | Sangamo Therapeutics To Present Neurology-Focused Pre-Clinical Data From Epigenetic Regulation, Capsid Delivery And Genome Engineering Platforms At 27th ASGCT Annual Meeting

Moomoo 24/7Apr 22 16:36 ET

Biotech Roundtable: Who Will Bring the Next CRISPR Drug to Market?

Seeking AlphaApr 2 11:36 ET

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Global Clinical Trials Review 2024, Featuring Takeda Pharmaceutical, JCR Pharmaceuticals, GC Corp, RegenxBio, Sangamo Therapeutics and Generium

Yahoo FinanceApr 2 09:48 ET

What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today

Yahoo FinanceMar 25 14:52 ET

Revenue Downgrade: Here's What Analysts Forecast For Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Today is shaping up negative for Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. There was a fairly drac

Simply Wall StMar 22 15:06 ET

12 Health Care Stocks Moving In Friday's Intraday Session

GainersIMAC Hldgs (NASDAQ:BACK) shares moved upwards by 91.5% to $2.47 during Friday's regular session. The market value of their outstanding shares is at $2.8 million. Virios Therapeutics (NASDAQ:VIR

BenzingaMar 22 13:31 ET

Express News | Sangamo Therapeutics Shares Are Trading Lower After the Company Announced the Pricing of a $24.0 Million Registered Direct Offering

Moomoo 24/7Mar 22 08:06 ET

Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform

H.C. Wainwright initiated coverage on Voyager Therapeutics Inc (NASDAQ:VYGR), noting a growing franchise of novel, highly-differentiated adeno-associated virus (AAV)-based TRACER capsids with the pote

BenzingaMar 19 14:16 ET

Express News | HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Raises Price Target to $5

Moomoo 24/7Mar 19 06:25 ET

Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says

Sangamo Therapeutics' (SGMO) emphasis remains on progressing neurology programs toward clinical development, Wedbush said in a report Thursday. The company reported Q4 results on Wednesday and provide

MT NewswiresMar 14 16:04 ET

Express News | RBC Capital Reiterates Sector Perform on Sangamo Therapeutics, Maintains $2 Price Target

Moomoo 24/7Mar 14 11:28 ET

Sangamo Therapeutics Full Year 2023 Earnings: Misses Expectations

Yahoo FinanceMar 14 09:26 ET

There's No Escaping Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Muted Revenues Despite A 50% Share Price Rise

Despite an already strong run, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares have been powering on, with a gain of 50% in the last thirty days. But the last month did very little to improve the 6

Simply Wall StMar 13 15:07 ET

4 Analysts Assess Sangamo Therapeutics: What You Need To Know

In the latest quarter, 4 analysts provided ratings for Sangamo Therapeutics (NASDAQ:SGMO), showcasing a mix of bullish and bearish perspectives.The following table summarizes their recent ratings, she

BenzingaMar 13 14:00 ET

Express News | HC Wainwright & Co. Maintains Buy on Sangamo Therapeutics, Maintains $3 Price Target

Moomoo 24/7Mar 13 12:48 ET

Sangamo Therapeutics Expects Total Operating Expenses In The Range Of ~$145M-$165M In 2024

Financial Guidance for 2024On a GAAP basis, we expect total operating expenses in the range of approximately $145 million to $165 million in 2024, which includes non-cash stock-based compensation expe

BenzingaMar 13 08:16 ET

Sangamo Therapeutics Q4 EPS $(0.34) Misses $(0.26) Estimate, Sales $2.04M Miss $8.10M Estimate

Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.26) by 30.77 percent. This is a 6.25 percent decrease over losses o

BenzingaMar 13 08:15 ET

Express News | Sangamo Therapeutics Announces Data From STAC-BBB Demonstrating 'Robust Penetration of the Blood-brain Barrier (BBB) and Strong Transgene Expression Throughout the Central Nervous System (CNS) of NHPs'

Moomoo 24/7Mar 13 08:06 ET

Sangamo Therapeutics 4Q Rev $2.04M >SGMO

Sangamo Therapeutics 4Q Rev $2.04M >SGMO

Dow JonesMar 13 08:05 ET

Press Release: Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results -- Data from novel proprietary neurotropic adeno-associated virus (AAV) deliv

Dow JonesMar 13 08:05 ET